Format

Send to

Choose Destination
See comment in PubMed Commons below
Neuropsychopharmacology. 2017 May 29. doi: 10.1038/npp.2017.106. [Epub ahead of print]

A Randomized, Double-Blind, Placebo-Controlled, Sequential Parallel Comparison Design Trial of Adjunctive Riluzole for Treatment-Resistant Major Depressive Disorder.

Author information

1
Mental Health Care Line, Michael E. DeBakey VA Medical Center, Houston, TX.
2
Menninger Department of Psychiatry &Behavioral Sciences, Baylor College of Medicine, Houston.
3
Department of Psychiatry, Yale University School of Medicine, New Haven, CT.
4
Department of Biostatistics, Yale School of Public Health, New Haven, CT.
5
Departments of Emergency Medicine and Anesthesiology, Yale University School of Medicine, New Haven, CT.
6
Department of Psychiatry, Massachusetts General Hospital, Boston, MA.

Abstract

Riluzole is a glutamate-modulating agent with neuroprotective properties approved for use in amyotrophic lateral sclerosis. The efficacy and safety of riluzole vs placebo as an adjunct to antidepressant medication in outpatients with major depressive disorder (MDD) was examined in a 3-site, 8-week, randomized, double-blind, placebo-controlled, fixed-dose trial using a sequential parallel comparison design comprised of two phases of 4 weeks. Patients with MDD in a current major depressive episode (N=104) with an inadequate response to either a prospective or a historical trial of an antidepressant medication were randomized in a 2 : 3 : 3 ratio to the treatment sequences of riluzole/riluzole, placebo/placebo, and placebo/riluzole, respectively. The primary outcome was change in depression severity, as assessed by the Montgomery-Åsberg Depression Rating Scale (MADRS). Secondary efficacy outcomes included the response rate, defined as at least a 50% improvement in MADRS, Clinical Global Impressions severity and improvement subscales, and patient-reported measures of depression and cognitive function. Eighty-five patients completed the randomized treatment phases. Treatment groups did not differ in mean change in MADRS scores, response rate, or in any secondary efficacy outcomes. Riluzole was generally well tolerated, with a side effect profile consistent with its clinical use. In conclusion, a fixed dose of riluzole (100 mg/day) did not show adjunctive antidepressant efficacy compared to placebo. The trial was adequately powered to detect a moderate riluzole effect, and the risk for exaggerated placebo responses was mitigated. The lack of efficacy suggests that mechanisms underlying riluzole's neuroprotective effects are insufficient for clinical response in treatment-resistant depression.Neuropsychopharmacology accepted article preview online, 29 May 2017. doi:10.1038/npp.2017.106.

PMID:
28553836
DOI:
10.1038/npp.2017.106
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Nature Publishing Group
    Loading ...
    Support Center